NCT02652871

LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Completed Phase 1 Last updated 15 November 2019

What this trial tests

Phase 1 trial testing LY2510924 in Leukemia in 36 participants. Completed in 16 July 2019.

Timeline

9 May 2016

Primary endpoint
16 July 2019

16 July 2019

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	36
Start date	9 May 2016
Primary completion	16 July 2019
Estimated completion	16 July 2019
Sites	1 location across United States

Drugs / interventions tested

• LY2510924 — full drug profile →
• Idarubicin (IDARUBICIN) — full drug profile →
• Cytarabine — full drug profile →

Conditions studied

• Leukemia — all drugs for Leukemia →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

Adults 18 to 70, any sex, with Leukemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical research study is to learn about the safety of LY2510924 in combination with cytarabine and idarubicin in patients with relapsed or refractory AML. We will also study if LY2510924 in combination with cytarabine and idarubicin can help to control relapsed or refractory AML.

LY2510924 is designed to help cancer cells move from the bone marrow into the bloodstream, where they are exposed to chemotherapy (in this case, cytarabine and idarubicin).

This is an investigational study. LY2510924 is not FDA approved or commercially available. Its use in this study is investigational. Cytarabine and idarubicin are approved to treat certain types of leukemia. Their use in this study in combination with LY2510924 is investigational.

Up to 36 patients will take part in this study. All will be enrolled at MD Anderson.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Targeting cytokine and chemokine signaling pathways for cancer therapy.
   Yi M, Li T, Niu M, Zhang H, et al · · 2024 · cited 264× · PMID 39034318 · DOI 10.1038/s41392-024-01868-3
2. Small molecule inhibitors targeting the cancers.
   Liu GH, Chen T, Zhang X, Ma XL, et al · · 2022 · cited 127× · PMID 36254250 · DOI 10.1002/mco2.181
3. Research trends in pharmacological modulation of tumor-associated macrophages.
   Wang N, Wang S, Wang X, Zheng Y, et al · · 2021 · cited 88× · PMID 33463063 · DOI 10.1002/ctm2.288
4. Targeting CXCR4 in AML and ALL.
   Cancilla D, Rettig MP, DiPersio JF. · · 2020 · cited 84× · PMID 33014834 · DOI 10.3389/fonc.2020.01672
5. Targeting of TAMs: can we be more clever than cancer cells?
   Kzhyshkowska J, Shen J, Larionova I. · · 2024 · cited 79× · PMID 39516356 · DOI 10.1038/s41423-024-01232-z
6. CXCR4 and CXCR7 Signaling Pathways: A Focus on the Cross-Talk Between Cancer Cells and Tumor Microenvironment.
   Santagata S, Ieranò C, Trotta AM, Capiluongo A, et al · · 2021 · cited 74× · PMID 33937018 · DOI 10.3389/fonc.2021.591386
7. Targeting the CXCL12/CXCR4 axis in acute myeloid leukemia: from bench to bedside.
   Cho BS, Kim HJ, Konopleva M. · · 2017 · cited 69× · PMID 28219003 · DOI 10.3904/kjim.2016.244
8. The cytokine network in acute myeloid leukemia.
   Luciano M, Krenn PW, Horejs-Hoeck J. · · 2022 · cited 52× · PMID 36248849 · DOI 10.3389/fimmu.2022.1000996